Incyte | INCY - مصروفات التشغيل





مصروفات التشغيل تغيير تاريخ
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agenus USD 19.81M 293.94M 2025-12
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
MacroGenics USD 53.32M 13.68M 2025-12
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.29B 507M 2026-03
Novartis USD 9.8B 23M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03